BiomeBank picks new Chair to accelerate commercialisation strategy

Australia-based BiomeBank has announced Chris Hall as the new Chair for the clinical stage biotechnology company, having recently served as Chief Investment Officer of Ellerston Capital. Prior to this, Hall served as Managing Director of Blackrock Asset Management (North-Asia Ltd). The appointment is effective as of January 17, 2022. Hall brings with him over 30 years experience and an impressive track record of investment management across both public and private markets within the APAC region. As the company moves towards closing its Series A funding round in early 2022 and formal TGA approval of its first-generation product, Hall’s experience in global markets will support its growth ambition into the Asia Pacific and European region.